BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) CFO Jason Keyes bought 700 shares of the business’s stock in a transaction on Monday, August 10th. The stock was bought at an average cost of $16.00 per share, with a total value of $11,200.00. Following the completion of the purchase, the chief financial officer directly owned 700 shares in the company, valued at approximately $11,200. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
BlossomHill Therapeutics Price Performance
Shares of BLSM traded down $0.01 during mid-day trading on Monday, reaching $15.99. The stock had a trading volume of 417,968 shares. BlossomHill Therapeutics, Inc. has a 52-week low of $15.25 and a 52-week high of $17.25.
Read More
- Five stocks we like better than BlossomHill Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
